目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 YEARS CONSIDERED
1.3.3 INCLUSIONS AND EXCLUSIONS
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.2.1 GLOBAL SINGLE-CELL ANALYSIS MARKET SIZE ESTIMATION
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 TOP-DOWN APPROACH
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN SINGLE-CELL ANALYSIS MARKET
4.2 NORTH AMERICA: SINGLE-CELL ANALYSIS MARKET, BY CELL TYPE AND COUNTRY
4.3 SINGLE-CELL ANALYSIS MARKET, BY PRODUCT, 2025 VS. 2030
4.4 SINGLE-CELL ANALYSIS MARKET, BY END USER
4.5 SINGLE-CELL ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Technological advancements in single-cell analysis products
5.2.1.2 Rising prevalence of cancer
5.2.1.3 Increasing R&D in pharmaceutical and biotechnology industries
5.2.1.4 Growth in stem cell research
5.2.1.5 Growing focus on personalized medicine
5.2.2 RESTRAINTS
5.2.2.1 High cost of single-cell analysis products
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of single-cell sequencing
5.2.3.2 Integration of microfluidics in single-cell analysis
5.2.3.3 Rising potential in emerging Asian markets
5.2.4 CHALLENGES
5.2.4.1 Lack of standardization in protocols and quality control procedures
5.2.4.2 Technical limitations of single-cell analysis
5.2.4.3 Mounting ethical and privacy concerns
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 VALUE CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 Flow cytometry
5.6.1.2 Next-generation sequencing
5.6.1.3 Polymerase chain reaction
5.6.1.4 Microscopy
5.6.1.5 Mass spectrometry
5.6.2 COMPLEMENTARY TECHNOLOGIES
5.6.2.1 Bioinformatics tools and computational analysis
5.6.2.2 Multi-omics integration
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 Nanotechnology
5.6.3.2 Artificial intelligence and machine learning
5.7 PATENT ANALYSIS
5.7.1 METHODOLOGY
5.7.2 PATENTS APPLIED AND GRANTED, 2014-2024
5.8 TRADE ANALYSIS
5.8.1 IMPORT DATA (HS CODE 9027)
5.8.2 EXPORT DATA (HS CODE 9027)
5.9 PORTER'S FIVE FORCES ANALYSIS
5.9.1 THREAT OF NEW ENTRANTS
5.9.2 THREAT OF SUBSTITUTES
5.9.3 BARGAINING POWER OF SUPPLIERS
5.9.4 BARGAINING POWER OF BUYERS
5.9.5 INTENSITY OF COMPETITIVE RIVALRY
5.10 TARIFF & REGULATORY LANDSCAPE
5.10.1 TARIFF DATA (HS CODE 9027)
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.3 REGULATORY FRAMEWORK
5.11 PRICING ANALYSIS
5.11.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS
5.11.2 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.13.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
5.13.3 BUYING CRITERIA
5.14 INVESTMENT AND FUNDING SCENARIO
5.15 IMPACT OF GENERATIVE AI ON SINGLE-CELL ANALYSIS MARKET
5.15.1 AI USE-CASES
5.15.2 KEY COMPANIES IMPLEMENTING AI
5.16 CASE STUDY ANALYSIS
5.16.1 COMPREHENSIVE SINGLE-CELL TRANSCRIPTOMIC ATLAS OF HUMAN CORNEA
5.16.2 MASSIVELY PARALLEL SINGLE-CELL RNA SEQUENCING IDENTIFIES RARE DRUG-RESISTANT CANCER SUBPOPULATIONS
5.16.3 SINGLE-CELL ANALYSIS OF RENAL CELL CARCINOMA REVEALS TUMOR HETEROGENEITY AND MICROENVIRONMENTAL COMPLEXITY
5.17 US 2025 TARIFF IMPACT OVERVIEW
5.17.1 INTRODUCTION
5.17.2 KEY TARIFF RATES
5.17.3 PRICE IMPACT ANALYSIS
5.17.4 KEY IMPACT ON VARIOUS REGIONS
5.17.4.1 US
5.17.4.2 Europe
5.17.4.3 Asia Pacific
5.17.4.4 Rest of the World
5.17.5 END-USE INDUSTRY IMPACT
5.17.5.1 Pharmaceutical and biotech companies
5.17.5.2 Contract research organizations (CROs)
5.17.5.3 Academic & research institutes

6 SINGLE-CELL ANALYSIS MARKET, BY APPLICATION
6.1 INTRODUCTION
6.2 RESEARCH APPLICATIONS
6.2.1 CANCER RESEARCH
6.2.1.1 Rising prevalence of cancer to drive market
6.2.2 IMMUNOLOGY RESEARCH
6.2.2.1 High incidence of immunological disorders to propel market
6.2.3 NEUROLOGY RESEARCH
6.2.3.1 Increasing incidence of neurological disorders to boost market
6.2.4 STEM CELL RESEARCH
6.2.4.1 Rising investments in stem cell research to drive market
6.2.5 OTHER RESEARCH APPLICATIONS
6.3 MEDICAL APPLICATIONS
6.3.1 NON-INVASIVE PRENATAL DIAGNOSIS
6.3.1.1 Increasing prevalence of genetic diseases to drive demand
6.3.2 IN VITRO FERTILIZATION
6.3.2.1 Growing demand for IVF procedures to support market
6.3.3 CIRCULATING TUMOR CELL DETECTION
6.3.3.1 Rising prevalence of cancer to contribute to segment growth

7 SINGLE-CELL ANALYSIS MARKET, BY CELL TYPE
7.1 INTRODUCTION
7.2 HUMAN CELLS
7.2.1 GROWING FUNDING FOR CANCER RESEARCH TO BOOST DEMAND
7.3 ANIMAL CELLS
7.3.1 INCREASING ANIMAL CELL RESEARCH TO DRIVE MARKET
7.4 MICROBIAL CELLS
7.4.1 RISING GOVERNMENT SUPPORT TO COMBAT ANTIMICROBIAL RESISTANCE TO PROPEL MARKET

8 SINGLE-CELL ANALYSIS MARKET, BY END USER
8.1 INTRODUCTION
8.2 ACADEMIC & RESEARCH LABORATORIES
8.2.1 INCREASING FUNDING FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET
8.3 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES
8.3.1 GROWTH IN DRUG DISCOVERY AND R&D ACTIVITIES TO BOOST MARKET
8.4 HOSPITALS & DIAGNOSTIC LABORATORIES
8.4.1 HIGH PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES TO DRIVE DEMAND
8.5 CELL BANKS & IVF CENTERS
8.5.1 RISING DEMAND FOR PERSONALIZED AND REGENERATIVE MEDICINE TO PROPEL MARKET

9 SINGLE-CELL ANALYSIS MARKET, BY PRODUCT
9.1 INTRODUCTION
9.2 CONSUMABLES
9.2.1 BEADS
9.2.1.1 Increasing use in research and genetic exploration to drive market
9.2.2 MICROPLATES
9.2.2.1 Rising frequency of product launches to boost market
9.2.3 REAGENTS
9.2.3.1 Advancements in single-cell genomics to increase demand
9.2.4 ASSAY KITS
9.2.4.1 Immunoassays
9.2.4.1.1 Growth in geriatric population to fuel demand
9.2.4.2 Cell-based assays
9.2.4.2.1 Increasing use in pharma and biopharma companies to drive market
9.2.5 OTHER CONSUMABLES
9.3 INSTRUMENTS
9.3.1 FLOW CYTOMETERS
9.3.1.1 Technological advancements to drive demand
9.3.2 NGS SYSTEMS
9.3.2.1 Increased affordability to support segment growth
9.3.3 PCR INSTRUMENTS
9.3.3.1 Rising use for DNA and mRNA amplification to boost market
9.3.4 SPECTROPHOTOMETERS
9.3.4.1 Technological advancements to boost market
9.3.5 CELL COUNTERS
9.3.5.1 Rising demand for automated cell counters to fuel market
9.3.6 MICROSCOPES
9.3.6.1 Increasing use in cell-based research to drive market
9.3.7 HCS SYSTEMS
9.3.7.1 Growing need for multi-parametric cell analysis to drive adoption
9.3.8 MICROARRAYS
9.3.8.1 Increasing development of targeted therapies to support market
9.3.9 OTHER INSTRUMENTS

10 SINGLE-CELL ANALYSIS MARKET, BY TECHNIQUE
10.1 INTRODUCTION
10.2 FLOW CYTOMETRY
10.2.1 INCREASING USE TO IDENTIFY CANCEROUS CELLS TO DRIVE MARKET
10.3 NEXT-GENERATION SEQUENCING
10.3.1 WIDE ADOPTION IN DRUG DISCOVERY TO DRIVE MARKET
10.4 POLYMERASE CHAIN REACTION
10.4.1 INCREASING APPLICATIONS OF DIGITAL PCR TO SUPPORT MARKET
10.5 MICROSCOPY
10.5.1 FOCUS ON DEVELOPMENT OF ADVANCED IMAGING SYSTEMS TO PROPEL MARKET
10.6 MASS SPECTROMETRY
10.6.1 LAUNCH OF ADVANCED PRODUCTS TO DRIVE MARKET
10.7 OTHER TECHNIQUES

11 SINGLE-CELL ANALYSIS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing R&D investments and funding to drive market
11.2.3 CANADA
11.2.3.1 High prevalence of hemophilia to propel market
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Growing awareness of advanced cell therapies to support market
11.3.3 UK
11.3.3.1 Growing adoption of single-cell analysis products to drive demand
11.3.4 FRANCE
11.3.4.1 Growing government funding for R&D to propel market
11.3.5 ITALY
11.3.5.1 Focus on cell biology research to drive market
11.3.6 SPAIN
11.3.6.1 Increasing number of biotechnology companies to drive demand
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Increasing R&D expenditure to support market
11.4.3 JAPAN
11.4.3.1 Increasing geriatric population to fuel demand
11.4.4 INDIA
11.4.4.1 Growing focus on development of cell-based therapies to boost market
11.4.5 SOUTH KOREA
11.4.5.1 Increasing number of strategic alliances to boost market
11.4.6 AUSTRALIA
11.4.6.1 Rising number of life science companies to boost demand
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Rising focus on biotechnology industry to bolster market
11.5.3 MEXICO
11.5.3.1 Government support for biopharmaceutical production to drive market
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
11.6.2 GCC
11.6.2.1 Saudi Arabia
11.6.2.1.1 Increasing healthcare expenditure to drive market
11.6.2.2 United Arab Emirates
11.6.2.2.1 Advancements in biopharmaceutical sector to drive demand
11.6.2.3 Rest of GCC
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 GROWING FUNDING FOR DEVELOPMENT AND PRODUCTION OF BIOPHARMACEUTICALS TO DRIVE MARKET
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
12.3 REVENUE ANALYSIS, 2022-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.4.1 RANKING OF KEY MARKET PLAYERS
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1 Company footprint
12.5.5.2 Product footprint
12.5.5.3 Region footprint
12.5.5.4 Technique footprint
12.5.5.5 Application footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1 Detailed list of key startups/SMEs
12.6.5.2 Competitive benchmarking of key startups/SMEs
12.7 COMPANY VALUATION AND FINANCIAL METRICS
12.8 BRAND/PRODUCT COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 PRODUCT LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 INTRODUCTION
13.2 KEY PLAYERS
13.2.1 BD
13.2.1.1 Business overview
13.2.1.2 Products offered
13.2.1.3 Recent developments
13.2.1.3.1 Product launches
13.2.1.3.2 Deals
13.2.1.4 MnM view
13.2.1.4.1 Key strengths
13.2.1.4.2 Strategic choices
13.2.1.4.3 Weaknesses and competitive threats
13.2.2 THERMO FISHER SCIENTIFIC INC.
13.2.2.1 Business overview
13.2.2.2 Products offered
13.2.2.3 Recent developments
13.2.2.3.1 Product launches
13.2.2.3.2 Deals
13.2.2.4 MnM view
13.2.2.4.1 Key strengths
13.2.2.4.2 Strategic choices
13.2.2.4.3 Weaknesses and competitive threats
13.2.3 DANAHER CORPORATION
13.2.3.1 Business overview
13.2.3.2 Products offered
13.2.3.3 Recent developments
13.2.3.3.1 Deals
13.2.3.4 MnM view
13.2.3.4.1 Key strengths
13.2.3.4.2 Strategic choices
13.2.3.4.3 Weaknesses and competitive threats
13.2.4 10X GENOMICS
13.2.4.1 Business overview
13.2.4.2 Products offered
13.2.4.3 Recent developments
13.2.4.3.1 Product launches
13.2.4.3.2 Deals
13.2.5 MERCK KGAA
13.2.5.1 Business overview
13.2.5.2 Products offered
13.2.5.3 Recent developments
13.2.5.3.1 Deals
13.2.6 AGILENT TECHNOLOGIES, INC.
13.2.6.1 Business overview
13.2.6.2 Products offered
13.2.6.3 Recent developments
13.2.6.3.1 Product launches
13.2.6.3.2 Deals
13.2.7 QIAGEN
13.2.7.1 Business overview
13.2.7.2 Products offered
13.2.7.3 Recent developments
13.2.7.3.1 Deals
13.2.8 ILLUMINA, INC.
13.2.8.1 Business overview
13.2.8.2 Products offered
13.2.8.3 Recent developments
13.2.8.3.1 Product launches
13.2.8.3.2 Deals
13.2.9 BIO-RAD LABORATORIES, INC.
13.2.9.1 Business overview
13.2.9.2 Products offered
13.2.9.3 Recent developments
13.2.9.3.1 Product launches
13.2.10 DIASORIN S.P.A.
13.2.10.1 Business overview
13.2.10.2 Products offered
13.2.10.3 Recent developments
13.2.10.3.1 Deals
13.2.11 STANDARD BIOTOOLS
13.2.11.1 Business overview
13.2.11.2 Product offered
13.2.11.3 Recent developments
13.2.11.3.1 Product launches
13.2.11.3.2 Deals
13.2.12 TECAN TRADING AG
13.2.12.1 Business overview
13.2.12.2 Products offered
13.2.12.3 Recent developments
13.2.12.3.1 Product launches
13.2.12.3.2 Deals
13.2.13 SARTORIUS AG
13.2.13.1 Business overview
13.2.13.2 Products offered
13.2.13.3 Recent developments
13.2.13.3.1 Deals
13.2.13.3.2 Expansions
13.2.14 CORNING INCORPORATED
13.2.14.1 Business overview
13.2.14.2 Products offered
13.2.15 CYTEK BIOSCIENCES
13.2.15.1 Business overview
13.2.15.2 Products offered
13.2.15.3 Recent developments
13.2.15.3.1 Product launches
13.2.15.3.2 Deals
13.2.15.3.3 Expansions
13.2.16 TAKARA BIO INC.
13.2.16.1 Business overview
13.2.16.2 Products offered
13.2.16.3 Recent developments
13.2.16.3.1 Product launches
13.2.16.3.2 Deals
13.2.17 BIOMERIEUX
13.2.17.1 Business overview
13.2.17.2 Products offered
13.2.17.3 Recent developments
13.2.17.3.1 Deals
13.2.18 REVVITY
13.2.18.1 Business overview
13.2.18.2 Products offered
13.2.18.3 Recent developments
13.2.18.3.1 Deals
13.2.19 BIO-TECHNE
13.2.19.1 Business overview
13.2.19.2 Products offered
13.2.19.3 Recent developments
13.2.19.3.1 Deals
13.2.20 PACBIO
13.2.20.1 Business overview
13.2.20.2 Products offered
13.2.20.3 Recent developments
13.2.20.3.1 Product launches
13.2.21 BRUKER
13.2.21.1 Business overview
13.2.21.2 Products offered
13.2.21.3 Recent developments
13.2.21.3.1 Product launches
13.2.21.3.2 Deals
13.2.22 PROMEGA CORPORATION
13.2.22.1 Business overview
13.2.22.2 Products offered
13.2.23 OXFORD NANOPORE TECHNOLOGIES PLC
13.2.23.1 Business overview
13.2.23.2 Products offered
13.2.23.3 Recent developments
13.2.23.3.1 Deals
13.3 OTHER PLAYERS
13.3.1 SINGLERON BIOTECHNOLOGIES
13.3.2 CELL MICROSYSTEMS
13.3.3 NANOCELLECT BIOMEDICAL
13.3.4 RARECYTE, INC.
13.3.5 BICO
13.3.6 MENARINI GROUP
13.3.7 APOGEE FLOW SYSTEMS LTD
13.3.8 CREATIVE BIOLABS
13.3.9 SPHERE BIO
13.3.10 YOKOGAWA ELECTRIC CORPORATION

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS